You are here: Industry Insights > Cosentyx

News List

FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents Pharmaceutical-Business-Review
December 27, 2021
A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine.
Cosentyx?displays a 72 percent reduced arthritis flare risk EuropeanPharmaceuticalReview
November 11, 2021
Novartis has announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx? (secukinumab?)...
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis pharmatimes
June 21, 2021
Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx? (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ...
FDA Approves Novartis Cosentyx for Children with Plaque Psoriasis americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in immuno-dermatology and rheumatology, announced that the FDA has approved Cosentyx? (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic ...
Cosentyx approved to treat plaque psoriasis in paediatric patients pharmatimes
June 03, 2021
The US Food and Drug Administration (FDA) has approved Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx for the treatment of children and adolescents with moderate to severe plaque psoriasis.
Cosentyx gains EU approval for new label extension pharmatimes
March 03, 2021
Novartis’ interleukin (IL)-17A inhibitor Cosentyx has gained an EU label update to include data for axial manifestations of psoriatic arthritis (PsA).
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study pharmatimes
November 06, 2020
Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study.
Financial Report: Novartis contractpharma
November 06, 2020
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
Cosentyx wins EU approval for first-line paediatric psoriasis pharmatimes
August 04, 2020
Novartis’ Cosentyx (secukinumab) has been granted approval by the European Commission as a treatment for moderate-to-severe plaque psoriasis in children and adolescents aged six to <18 years.